Authorized purpose: BriefCase analyzes contrast-enhanced chest CT for suspected pulmonary embolism and notifies or prioritizes the study in the labeled hospital or cloud worklist workflow; the output is not a primary diagnosis.
Clinical role
CT image networking, processing, enhancement, triage, measurement, or professional workflow support.
Images and patients
CT/CTA · Chest/Lung
Key limitation
Keep in mind: Input protocol, contrast, anatomy, model, software version, output review, and local integration limits are release-specific. BriefCase analyzes contrast-enhanced chest CT for suspected pulmonary embolism and notifies or prioritizes the study in the labeled hospital or cloud worklist workflow; the output is not a primary diagnosis.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: BriefCase analyzes contrast-enhanced chest CT for suspected pulmonary embolism and notifies or prioritizes the study in the labeled hospital or cloud worklist workflow; the output is not a primary diagnosis.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Chest/Lung Input: Supported CT or CTA DICOM images and the metadata required by the exact release-specific processing workflow.
Who uses it?Intended users: Qualified radiologists and other trained imaging professionals.
What does the software produce?Output: Processed CT image objects, measurements, notifications, or worklist outputs for professional review.
What is its most important limitation?Key limitation: Input protocol, contrast, anatomy, model, software version, output review, and local integration limits are release-specific. BriefCase analyzes contrast-enhanced chest CT for suspected pulmonary embolism and notifies or prioritizes the study in the labeled hospital or cloud worklist workflow; the output is not a primary diagnosis.
Clinical takeaway. Clinical role: BriefCase analyzes contrast-enhanced chest CT for suspected pulmonary embolism and notifies or prioritizes the study in the labeled hospital or cloud worklist workflow; the output is not a primary diagnosis.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports a retrospective, blinded, multicenter study of 268 contrast-enhanced chest CTs (74 positive, 194 negative) from 2 US sites for incidental pulmonary embolism: sensitivity 90.5% (95% CI: 81.4%, 96.2%) and specificity 88.7% (95% CI: 83.3%, 92.8%). In 63 true positive cases, time-to-notification was 4.7 minutes versus 223.3 minutes for standard-of-care time-to-exam-open. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
BriefCase analyzes contrast-enhanced chest CT for suspected pulmonary embolism and notifies or prioritizes the study in the labeled hospital or cloud worklist workflow; the output is not a primary diagnosis.
Input protocol, contrast, anatomy, model, software version, output review, and local integration limits are release-specific. BriefCase analyzes contrast-enhanced chest CT for suspected pulmonary embolism and notifies or prioritizes the study in the labeled hospital or cloud worklist workflow; the output is not a primary diagnosis.
The exact FDA document reports a retrospective, blinded, multicenter study of 268 contrast-enhanced chest CTs (74 positive, 194 negative) from 2 US sites for incidental pulmonary embolism: sensitivity 90.5% (95% CI: 81.4%, 96.2%) and specificity 88.7% (95% CI: 83.3%, 92.8%). In 63 true positive cases, time-to-notification was 4.7 minutes versus 223.3 minutes for standard-of-care time-to-exam-open. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Aidoc conducted a retrospective, blinded, multicenter study with the BriefCase software with the primary endpoint to evaluate the software’s performance in identifying Contrast-enhanced chest CTs (but not dedicated CTPA protocol), containing Incidental Pulmonary Embolism in 268 cases from 2 clinical study sites in the US." … "There were 74 positive cases and 194 negative cases (images with iPE versus without iPE) included in the analysis.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports a retrospective, blinded, multicenter study of 268 contrast-enhanced chest CTs (74 positive, 194 negative) from 2 US sites for incidental pulmonary embolism: sensitivity 90.5% (95% CI: 81.4%, 96.2%) and specificity 88.7% (95% CI: 83.3%, 92.8%). In 63 true positive cases, time-to-notification was 4.7 minutes versus 223.3 minutes for standard-of-care time-to-exam-open. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Aidoc conducted a retrospective, blinded, multicenter study with the BriefCase software with the primary endpoint to evaluate the software’s performance in identifying Contrast-enhanced chest CTs (but not dedicated CTPA protocol), containing Incidental Pulmonary Embolism in 268 cases from 2 clinical study sites in the US." … "There were 74 positive cases and 194 negative cases (images with iPE versus without iPE) included in the analysis.". Read from the exact FDA decision document on 2026-11-14.
Standalone sensitivity for incidental pulmonary embolism on 268 contrast-enhanced chest CTs from 2 US sites: 90.5% (95% CI 81.4%-96.2%).
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Aidoc conducted a retrospective, blinded, multicenter study with the BriefCase software with the primary endpoint to evaluate the software’s performance in identifying Contrast-enhanced chest CTs (but not dedicated CTPA protocol), containing Incidental Pulmonary Embolism in 268 cases from 2 clinical study sites in the US." … "Specifically, sensitivity was 90.5% (95% CI: 81.4%, 96.2%) and specificity was 88.7% (95% CI: 83.3%, 92.8%).". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
Standalone specificity for incidental pulmonary embolism on 268 contrast-enhanced chest CTs from 2 US sites: 88.7% (95% CI 83.3%-92.8%).
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Aidoc conducted a retrospective, blinded, multicenter study with the BriefCase software with the primary endpoint to evaluate the software’s performance in identifying Contrast-enhanced chest CTs (but not dedicated CTPA protocol), containing Incidental Pulmonary Embolism in 268 cases from 2 clinical study sites in the US." … "Specifically, sensitivity was 90.5% (95% CI: 81.4%, 96.2%) and specificity was 88.7% (95% CI: 83.3%, 92.8%).". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
FDA submission-specific verification and validation evidence for K201020
DesignRegulatory verification, validation, and labeling evidence reviewed for exact FDA submission K201020.
PopulationThe labeled population and test materials for exact submission K201020; a general clinical study population is not established here.
Scopeexact submission
Tested versionBriefCase (K201020)
IndependenceSponsor or vendor study
K201020
FDA regulatory evidence is submission-specific but is not independent clinical performance evidence.
5 unlinked candidate evidence records are retained for source review and excluded from this evidence display.
Safety and lifecycle
Postmarket record
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
Not established in reviewed sources
Reviewed sources checked
Exact FDA submission
Checked 2026-09-04
No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.
Pricing & contractsPublic price, contract terms, and reimbursement
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported CT or CTA DICOM images and the metadata required by the exact release-specific processing workflow.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes BriefCase receiving and de-identifying DICOM images before processing, sending notifications to the Worklist desktop application, and prompting the user to assess the original images in the PACS. Interface versions and local compatibility require confirmation.
Scope: Exact FDA submission. Packet wording: "DICOM images are received, saved, filtered and de-identified before processing." … "The software then flags suspect cases by sending notifications to the Worklist desktop application, thereby prompting preemptive triage and prioritization by the attending radiologist.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes BriefCase as three modules (an Aidoc Hospital Server for image acquisition, an Aidoc Cloud Server for image processing, and an Aidoc Worklist Application installed on the radiologist's desktop), with exams de-identified and uploaded to the cloud for analysis. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "The device consists of the following three modules: (1) Aidoc Hospital Server (AHS) for image acquisition; (2) Aidoc Cloud Server (ACS) for image processing; and (3) Aidoc Worklist Application for workflow integration, installed on the radiologist’ desktop" … "The BriefCase time-to-notification includes the time to get the DICOM exam, de-identify it, upload it to the cloud, analyze and send a notification on a positive suspect case back to the worklist application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Processed CT image objects, measurements, notifications, or worklist outputs for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes BriefCase as three modules (an Aidoc Hospital Server for image acquisition, an Aidoc Cloud Server for image processing, and an Aidoc Worklist Application installed on the radiologist's desktop), with exams de-identified and uploaded to the cloud for analysis. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "The device consists of the following three modules: (1) Aidoc Hospital Server (AHS) for image acquisition; (2) Aidoc Cloud Server (ACS) for image processing; and (3) Aidoc Worklist Application for workflow integration, installed on the radiologist’ desktop" … "The BriefCase time-to-notification includes the time to get the DICOM exam, de-identify it, upload it to the cloud, analyze and send a notification on a positive suspect case back to the worklist application.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
The exact FDA package describes BriefCase receiving and de-identifying DICOM images before processing, sending notifications to the Worklist desktop application, and prompting the user to assess the original images in the PACS. Interface versions and local compatibility require confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "DICOM images are received, saved, filtered and de-identified before processing." … "The software then flags suspect cases by sending notifications to the Worklist desktop application, thereby prompting preemptive triage and prioritization by the attending radiologist.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Aidoc's current public Security & Privacy page says its security work is led by a CISO and security team, that it has adopted the NIST Cybersecurity Framework, and that its platform runs on AWS and Azure using EDR, encryption, SIEM and CSPM tooling. The page's list of standards and certifications did not load as readable text, so no certification is stated here.
Vendor-wide
Checked 2026-10-25
Vendor-wide marketing statement, not an independent attestation. It does not establish certificate scope or expiry, the controls of this exact release, data location, retention, identity and access, or incident-response terms for a deployed configuration. Obtain these from the vendor.
Aidoc's security page states that its platform runs on AWS and Azure and that customer data protection is achieved with the use of EDR, encryption, SIEM, CSPM and other technologies.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names Aidoc's platform generally and does not scope these capabilities to any specific product release; exact-release scope is not established. The page lists technology categories in use; it states no uptime, alerting or response-time SLAs.
Current vendor material is product-family context for K201020 only; exact release, enabled options, deployment, and local interoperability require confirmation.
product family · checked 2026-09-04
Vendor material is not exact-release evidence unless that linkage is separately proven.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
14Source classes checked
20Screened PubMed leads
6Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains 20 PubMed and 6 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 6 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not applicable - checked 2026-09-04 - Not applicable
CMS index context was checked, but no product-specific coverage or reimbursement determination is inferred.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-10-27 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: BriefCase is a radiological computer aided triage and notification software indicated for use in the analysis of CTPA images in adults or transitional adolescents aged 18 and older. The device is intended to assist hospital networks and appropriately trained medical specialists in workflow triage by flagging and communication of suspected positive findings of Pulmonary Embolism (PE) pathologies. Briefcase uses an artificial intelligence algorithm to analyze images and highlight cases with detected findings on a Stand-Alone Performance desktop application in parallel to the ongoing standard of care image interpretation. The user is presented with notifications for cases with suspected PE findings. Notifications include compressed preview images that are meant for informational purposes only and not intended for diagnostic use beyond notification. The device does not alter the original medical image and is not intended to be used as a diagnostic device. The results of BriefCase are intended to be used in conjunction with other patient information and based on their professional judgment, to assist with triage/prioritization of medical images. Notified clinicians are responsible for viewing full images per the standard of care.
Authorized purpose: BriefCase is a radiological computer aided triage and notification software indicated for use in the analysis of contrast-enhanced chest CTs (not dedicated CTPA protocol) in adults or transitional adolescents age 18 and older. The device is intended to assist hospital networks and appropriately trained medical specialists in workflow triage by flagging and communication of suspect cases of incidental Pulmonary Embolism (iPE) pathologies. The device is intended to be used on single energy exams only. Briefcase uses an artificial intelligence algorithm to analyze images and flag suspect cases on a Stand-Alone Performance desktop application in parallel to the ongoing standard of care image interpretation. The user is presented with notifications for suspect cases. Notifications include compressed preview images that are meant for informational purposes only and not intended for diagnostic use beyond notification. The device does not alter the original medical image and is not intended tobe used as a diagnostic device. The results of BriefCase are intended to be used in conjunction with other patient information and based on their professional judgment, to assist with triage/prioritization of medical images. Notified clinicians are responsible for viewing full images per the standard of care.
Authorized purpose: V5med Lung AI provides concurrent-read adjunctive notification of suspected pulmonary nodules on chest CT; it does not replace radiologist judgment, diagnostic processes, or review of original CT series.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.